candesartan cilexetil has been researched along with Coronary Stenosis in 2 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Coronary Stenosis: Narrowing or constriction of a coronary artery.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Preumont, N | 1 |
| Unger, P | 1 |
| Goldman, S | 1 |
| Berkenboom, G | 1 |
| Yoshida, O | 1 |
| Hirayama, H | 1 |
| Nanasato, M | 1 |
| Watanabe, T | 1 |
| Murohara, T | 1 |
1 trial available for candesartan cilexetil and Coronary Stenosis
| Article | Year |
|---|---|
The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Benzimidaz | 2005 |
1 other study available for candesartan cilexetil and Coronary Stenosis
| Article | Year |
|---|---|
Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Belgium; Benzimidazoles; Biphenyl Com | 2004 |